EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Is the salivary concentration of lamotrigine and levetiracetam associated with clinical outcome?

Paola Vassallo, Eva Choong, Irene Aícua-Rapún, Camille Stampfli, Pascal André, Andrea O Rossetti, Thierry Buclin, Laurent A Decosterd, Jan Novy

Epilepsy & Behavior · 2025

DOI: 10.1016/j.yebeh.2025.110595 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Epilepsy & Behavior, 2025. Verfasst von Paola Vassallo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Neurosciences, Neurology Service, University Hospital (CHUV) and Faculty of Biology and Medicine of Lausanne, Switzerland; Dep…. Hauptthemen laut MEDLINE: Anticonvulsants, Saliva, Epilepsy, Triazines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swiss National Scientific Foundation, Novartis Stiftung für Medizinisch-Biologische Forschung, Swiss National Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: The correlation between plasma and saliva concentration of anti-seizure medication (ASM) is well established, but variability limits the acceptance of saliva-based Therapeutic Drug Monitoring (TDM). We analysed the correlation between salivary levetiracetam and lamotrigine levels, and efficacy and tolerability. METHODS: Blood and saliva samples were collected over two years. Seizure freedom was defined as three times the longest pre-treatment inter-seizure interval or at least one year seizure-free without treatment changes. Adverse effects were assessed during visits. Lamotrigine and levetiracetam saliva and plasma concentrations were compared across groups based on treatment response and adverse effects. Response and adverse events predictors were analysed using binary logistic regression. RESULTS: Among 296 adults with epilepsy, 84 (28 %) achieved seizure freedom. These patients were older, predominantly on monotherapy, and underwent fewer ASM trials. 27 patients (9 %) reported adverse effects and were older at epilepsy onset. Seizure-free lamotrigine users had a lower dosage (median 2 vs 3.3 mg/kg, p = 0.07), and lower plasma and salivary concentrations (median plasma 2.6 vs 3.9 mg/L, p = 0.026; median saliva 1.4 vs 2.4 mg/L, p = 0.011). No association was found between lamotrigine dosage, levels, and adverse events. Levetiracetam users reporting side effects had higher salivary concentrations (median 20 vs 14.40 mg/L, p = 0.04), while seizure-free individuals showed no difference in salivary levels, although dosages and plasma levels differed. CONCLUSION: This study highlights the clinical relevance of saliva TDM, linking salivary drug levels to treatment response for lamotrigine and adverse effects for levetiracetam. Salivary ASMs levels may complement plasma TDM, enhancing individualised treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticonvulsantsSalivaEpilepsyTriazinesPiracetamHumansLevetiracetamLamotrigineMaleFemaleMiddle AgedAdultAgedTreatment OutcomeYoung AdultDrug MonitoringAdolescent

Stichwörter der Autor:innen

LamotrigineLevetiracetamSalivaTherapeutic drug monitoring

Substanzen

LevetiracetamLamotrigineAnticonvulsantsTriazinesPiracetam

Autor:innen und Institutionen

  • Department of Clinical Neurosciences, Neurology Service, University Hospital (CHUV) and Faculty of Biology and Medicine of Lausanne, Switzerland; Department of Clinical and Experimental Epilepsy, UCL Queen Square Instit…
  • Service and Laboratory of Clinical Pharmacology, University Hospital (CHUV) and Faculty of Biology and Medicine, Lausanne, Switzerland. Electronic address: Eva.Choong@chuv.ch.
  • Department of Clinical Neurosciences, Neurology Service, University Hospital (CHUV) and Faculty of Biology and Medicine of Lausanne, Switzerland. Electronic address: Irene.AicuaRapun@ksb.ch.
  • Service and Laboratory of Clinical Pharmacology, University Hospital (CHUV) and Faculty of Biology and Medicine, Lausanne, Switzerland. Electronic address: Camille.Stampfli@chuv.ch.
  • Service and Laboratory of Clinical Pharmacology, University Hospital (CHUV) and Faculty of Biology and Medicine, Lausanne, Switzerland. Electronic address: pascal.andre@chuv.ch.
  • Department of Clinical Neurosciences, Neurology Service, University Hospital (CHUV) and Faculty of Biology and Medicine of Lausanne, Switzerland. Electronic address: Andrea.Rossetti@chuv.ch.

Förderung

  • Swiss National Scientific Foundation
  • Novartis Stiftung für Medizinisch-Biologische Forschung
  • Swiss National Science Foundation

Zitieren

APA

Vassallo, P., Choong, E., Aícua-Rapún, I., Stampfli, C., André, P., Rossetti, A. O., Buclin, T., Decosterd, L. A., & Novy, J. (2025). Is the salivary concentration of lamotrigine and levetiracetam associated with clinical outcome?. Epilepsy & Behavior. https://doi.org/10.1016/j.yebeh.2025.110595

Vancouver

Vassallo P, Choong E, Aícua-Rapún I, Stampfli C, André P, Rossetti AO, et al. Is the salivary concentration of lamotrigine and levetiracetam associated with clinical outcome?. Epilepsy & Behavior. 2025. doi:10.1016/j.yebeh.2025.110595

BibTeX
@article{Vassallo2025,
  author = {Vassallo, Paola and Choong, Eva and Aícua-Rapún, Irene and Stampfli, Camille and André, Pascal and Rossetti, Andrea O and Buclin, Thierry and Decosterd, Laurent A and Novy, Jan},
  title = {Is the salivary concentration of lamotrigine and levetiracetam associated with clinical outcome?},
  journal = {Epilepsy & Behavior},
  year = {2025},
  doi = {10.1016/j.yebeh.2025.110595}
}
Kostenlos starten →